Johnson & Johnson (NYSE:JNJ) Shares Acquired by Greenspring Advisors LLC

Greenspring Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.3% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,564 shares of the company’s stock after purchasing an additional 147 shares during the quarter. Greenspring Advisors LLC’s holdings in Johnson & Johnson were worth $809,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of JNJ. Norges Bank acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $4,172,929,000. BlackRock Inc. lifted its stake in Johnson & Johnson by 2.6% in the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after buying an additional 4,982,885 shares in the last quarter. GQG Partners LLC lifted its stake in Johnson & Johnson by 1,109.4% in the 4th quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock valued at $676,375,000 after buying an additional 3,627,424 shares in the last quarter. State Street Corp lifted its stake in Johnson & Johnson by 1.8% in the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after buying an additional 2,492,359 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. lifted its stake in Johnson & Johnson by 5,036.2% in the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 1,227,558 shares of the company’s stock valued at $217,560,000 after buying an additional 1,203,658 shares in the last quarter. 68.78% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Credit Suisse Group upped their target price on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Daiwa Capital Markets assumed coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating on the stock. The Goldman Sachs Group upped their target price on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Citigroup reduced their target price on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $189.89.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is owned by insiders.

Johnson & Johnson Trading Down 0.4 %

JNJ stock opened at $171.11 on Friday. The company has a market cap of $449.88 billion, a price-to-earnings ratio of 24.91, a PEG ratio of 3.32 and a beta of 0.59. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. The business has a fifty day simple moving average of $175.21 and a 200-day simple moving average of $174.55. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.48 EPS. On average, equities research analysts expect that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.64%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.